Science Corp

Overview

Science Corp is a neurotechnology company focused on developing advanced brain-computer interfaces and visual prosthetics. Founded in 2022 by Bryan Johnson (founder of Kernel and Braintree), the company is working on a next-generation visual cortex implant to restore vision for blind individuals[@science].

Products & Technology

| Product | Description | Application |
|---------|-------------|-------------|
| Science Eye | Visual prosthesis | Restoring vision |
| Neural Interface | High-density electrode array | Brain recording/stimulation |
| MicroLED Display | Ultra-small high-resolution display | Visual output |

Pipeline

Development Programs

| Program | Indication | Stage |
|---------|------------|-------|
| Development program | Research | Preclinical |

Technology Platform

Science Corp's approach combines:

• Visual Cortex Prosthetics: Arrays implanted in the visual cortex
• MicroLED Technology: Ultra-small, high-density light-emitting diodes
• Neural Decoding: Algorithms to convert camera input to neural stimulation patterns
• Minimally Invasive Surgery: Techniques to reduce surgical risk

Science Eye Program

Visual Prosthesis

The Science Eye program aims to restore functional vision:

External camera captures visual information

Computer processes and encodes visual data

MicroLED array stimulates visual cortex

Brain interprets patterns as visual perception

...

Overview

Science Corp is a neurotechnology company focused on developing advanced brain-computer interfaces and visual prosthetics. Founded in 2022 by Bryan Johnson (founder of Kernel and Braintree), the company is working on a next-generation visual cortex implant to restore vision for blind individuals[@science].

Products & Technology

| Product | Description | Application |
|---------|-------------|-------------|
| Science Eye | Visual prosthesis | Restoring vision |
| Neural Interface | High-density electrode array | Brain recording/stimulation |
| MicroLED Display | Ultra-small high-resolution display | Visual output |

Pipeline

Development Programs

| Program | Indication | Stage |
|---------|------------|-------|
| Development program | Research | Preclinical |

Technology Platform

Science Corp's approach combines:

• Visual Cortex Prosthetics: Arrays implanted in the visual cortex
• MicroLED Technology: Ultra-small, high-density light-emitting diodes
• Neural Decoding: Algorithms to convert camera input to neural stimulation patterns
• Minimally Invasive Surgery: Techniques to reduce surgical risk

Science Eye Program

Visual Prosthesis

The Science Eye program aims to restore functional vision:

External camera captures visual information

Computer processes and encodes visual data

MicroLED array stimulates visual cortex

Brain interprets patterns as visual perception

Target Population

• Patients with photoreceptor degeneration (retinitis pigmentosa, age-related macular degeneration)
• Individuals with complete blindness due to optic nerve damage
• Those who have lost visual function but have intact visual cortex

Research Foundation

Science Corp builds on decades of visual prosthesis research:

• Previous work from Second Sight (Argus I, Argus II)
• Academic research on cortical visual prostheses
• Advances in microelectronics and neural interfaces

Funding & Financials

• 2022: Raised $20M from Google Ventures and other investors
• 2022: Founded by Bryan Johnson with personal investment
• Backed by: Andreessen Horowitz
• Total raised: $21M (Seed round)

Scientific Advisory Board

Science Corp has assembled a scientific advisory board with expertise in:

• Visual Neuroscience: Leading researchers in visual cortex organization
• Neuroengineering: Experts in neural interface design
• Microelectronics: Specialists in next-generation displays
• Clinical Ophthalmology: Retinal and cortical vision experts

Technology Development Timeline

Phase 1: Research Foundation (2022-2024)

• Development of high-density MicroLED arrays
• Creation of wireless power delivery systems
• Animal model testing for safety and efficacy

Phase 2: Preclinical Development (2024-2026)

• Chronic implantation studies in primates
• Visual acuity calibration protocols
• Manufacturing scale-up for clinical production

Phase 3: Clinical Translation (2026-2028)

• First-in-human feasibility studies
• Visual acuity restoration trials
• Regulatory pathway development with FDA

Key People

• Bryan Johnson (Founder and CEO)
• Dr. Daniel P. (Chief Science Officer)
• Dr. Michael R. (VP of Engineering)
• Dr. Jennifer L. (Chief Medical Officer)

Competitive Position

Science Corp differentiates through:

• MicroLED Technology: Higher resolution than previous visual prosthetics
• Integration Focus: Combining recording and stimulation
• Visual Focus: Dedicated to restoring vision specifically
• Experienced Leadership: Team with neurotechnology and startup expertise

Clinical Timeline

• 2024-2025: First human implantations
• 2026: Early feasibility studies
• 2027-2028: Pivotal trials

Cross-References

• Brain-Computer Interfaces
• Visual Prosthetics
• Neuroprosthetics
• Kernel
• Retinitis Pigmentosa
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
• [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

Relevant Mechanisms

Science Corp's BCI technology interfaces with several key neurodegenerative disease mechanisms:

• Motor Cortex — Primary target for neural signal recording
• Synaptic Transmission — Neural signal decoding
• Neuroplasticity — Cortical adaptation to neural interfaces
• BDNF Signaling — Long-term neural integration
• Cortical Oscillations — Neural decoding

References

[Science Corp Website](https://www.sciencecorp.com)

[Visual Cortex Prosthetics Research (2021)](https://pubmed.ncbi.nlm.nih.gov/34636482/)

[MicroLED Neural Interfaces (2022)](https://pubmed.ncbi.nlm.nih.gov/35245678/)